

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Musculoskeletal disease</b>				
Bone repair	Myocilin (MYOC)	<p>Cell culture and mouse studies suggest MYOC could improve the efficacy of mesenchymal stem cell (MSC) therapy for bone repair. In both mouse and human MSCs, addition of MYOC increased differentiation into osteoblasts compared with no MYOC addition. <i>Myoc</i>-deficient mice showed decreased cortical bone thickness compared with wild-type mice. Next steps could include identifying the molecular target by which MYOC enhances MSC differentiation into osteoblasts and developing molecules against the target.</p> <p><b>SciBX 6(21); doi:10.1038/scibx.2013.521</b>  <b>Published online May 30, 2013</b></p>	Unpatented; licensing status not applicable	<p>Kwon, H.S. <i>et al. J. Biol. Chem.</i>; published online April 29, 2013; doi:10.1074/jbc.M112.422972  <b>Contact:</b> Stanislav I. Tomarev, National Institutes of Health, Bethesda, Md.                      e-mail: <a href="mailto:tomarevs@nei.nih.gov">tomarevs@nei.nih.gov</a></p>